Skip to main content

Advertisement

SpringerLink
Log in

Semaglutide cost saving in T2DM

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. proportion of glycoslyated haemoglobin

  2. active pharmaceutical ingredient

References

  1. JOHANSEN P, et al. Cost-Effectiveness of Once-Weekly Semaglutide 1.0 mg vs. Dulaglutide 1.5 mg as Add-On to Metformin in the Treatment of Type 2 Diabetes in Canada. 78th Annual Scientific Sessions of the American Diabetes Association : (plus poster) abstr. 136-LB, 22 Jun 2018. Available from: URL: https://plan.core-apps.com/tristar_ada18/abstract/5188446740e191fd289345d56a7bb3a6.

  2. EILERMAN B, et al. Software Price Modeling of Semaglutide. 78th Annual Scientific Sessions of the American Diabetes Association : (plus poster) abstr. 144-LB, 22 Jun 2018. Available from: URL: https://plan.core-apps.com/tristar_ada18/abstract/5188446740e191fd289345d56a7aad3f.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Semaglutide cost saving in T2DM. PharmacoEcon Outcomes News 807, 31 (2018). https://doi.org/10.1007/s40274-018-5110-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-5110-0

Search

Navigation